Phathom Pharmaceuticals, Inc. Common Stock PHAT
Analyst Ratings
- Consensus
- Buy — 4 Buy · 1 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $18.80 (+216.5% upside)
Key Stats
- Today's Range
- $5.70 – $6.06
- 50-Day Range
- $5.01 – $9.74
- 52-Week Range
- $5.01 – $18.31
- Volume
- 2.11 million shs
- Average Volume
- 1.47 million shs
- Market Cap
- $464.37 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.01%
- Days to Cover
- 1.00
About Phathom Pharmaceuticals, Inc. Common Stock
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Related Stocks
Compare head-to-head: PHAT vs LLY·PHAT vs JNJ·PHAT vs ABBV·PHAT vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.